#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14640	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2243	649.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1720	1720	T	820	T,C	764,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14640	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2243	649.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1454	1454	C	864	C	830	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26744	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3570	746.4	0	.	n	.	0	T695C	SNP	695	695	T	964	964	C	769	C,T	727,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26744	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3570	746.4	0	.	n	.	0	A1638G	SNP	1638	1638	A	1907	1907	G	863	G	816	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26744	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3570	746.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2240	2240	C	872	C,T	816,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26744	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3570	746.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2314	2314	A	858	A	818	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26744	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3570	746.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2866	2866	C	846	C,A	802,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	R7Q	NONSYN	19	21	CGG	294	296	CAG	147;150;152	C;A;G	135;139;139	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	D29N	NONSYN	85	87	GAT	360	362	AAT	178;177;179	A;A;T	168;167;170	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	P68S	NONSYN	202	204	CCG	477	479	TCG	170;171;170	T;C;G	156;161;161	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	F72Y	NONSYN	214	216	TTC	489	491	TAT	185;186;185	T;A;T	176;173;175	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	P74S	NONSYN	220	222	CCG	495	497	TCG	180;181;180	T;C;G	171;172;169	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	P75del	DEL	223	223	C	498	498	C	178	C	167	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	E76D	NONSYN	226	228	GAA	499	501	CTG	177;174;173	C;T;G	166;163;163	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	A90V	NONSYN	268	270	GCG	540	542	GTG	146;147;146	G;T;G	138;128;135	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	A91V	NONSYN	271	273	GCG	543	545	GTT	145;146;147	G;T;T	139;138;142	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	V97I	NONSYN	289	291	GTC	561	563	ATC	154;153;153	A;T;C	147;147;148	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	R136C	NONSYN	406	408	CGC	678	680	TGT	171;169;168	T;G;T	160;159;155	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	R148Q	NONSYN	442	444	CGG	714	716	CAG	164;166;163	C;A,G;G	155;156,1;153	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	T153N	NONSYN	457	459	ACC	729	731	AAC	167;168;171	A;A;C	158;158;161	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	D156I	NONSYN	466	468	GAC	738	740	ATT	178;176;179	A;T;T	166;166;169	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	0	.	p	.	0	G195_F196insSG	INS	583	583	G	855	855	G	145	G	135	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1766	folP	855	855	94.82	folP.l15.c17.ctg.1	1425	122.7	1	SNP	p	R229S	1	R229S	NONSYN	685	687	CGC	963	965	AGC	187;187;188	A;G;C	181;180;180	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5056	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3624	139.0	1	SNP	p	S91F	0	.	.	271	273	TCC	667	669	TCC	182;182;181	T;C,T;C	168;167,1;169	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5056	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3624	139.0	1	SNP	p	D95N	0	.	.	283	285	GAC	679	681	GAC	182;182;184	G;A,C;C	173;170,1;173	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5056	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3624	139.0	1	SNP	p	D95G	0	.	.	283	285	GAC	679	681	GAC	182;182;184	G;A,C;C	173;170,1;173	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1534	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1382	110.8	0	.	p	.	0	W49trunc	TRUNC	145	145	T	540	540	T	166	T	151	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1534	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1382	110.8	1	SNP	p	G45D	0	.	.	133	135	GGC	528	530	GGC	154;153;154	G;G,A;C	144;139,1;141	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	858	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1110	76.9	0	.	n	.	0	.206T	INS	206	206	T	712	712	T	207	T	200	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4748	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3024	156.5	1	SNP	p	D86N	0	.	.	256	258	GAC	697	699	GAC	182;181;181	G;A;C,G	173;169;174,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4748	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3024	156.5	1	SNP	p	S87I	0	.	.	259	261	AGT	700	702	AGT	182;184;182	A;G;T	175;175;173	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4748	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3024	156.5	1	SNP	p	S87R	0	.	.	259	261	AGT	700	702	AGT	182;184;182	A;G;T	175;175;173	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4748	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3024	156.5	1	SNP	p	S87W	0	.	.	259	261	AGT	700	702	AGT	182;184;182	A;G;T	175;175;173	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4748	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3024	156.5	1	SNP	p	S88P	0	.	.	262	264	TCC	703	705	TCC	180;179;178	T;C;C	173;173;172	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4198	parE	1986	1986	100.0	parE.l15.c30.ctg.1	2765	151.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1612	1614	GGC	192;193;194	G;G;C	180;180;183	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.19.001	penA.19.001	1	1	27	3922	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2429	160.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1307	1309	GCA	196;194;194	G;C,T;A	183;179,1;184	penA.19.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3922	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2429	160.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1310	1312	ATC	194;196;199	A;T;C	184;184;188	penA.19.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3922	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2429	160.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1322	1324	GTG	191;189;190	G;T;G	180;177;180	penA.19.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3922	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2429	160.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1322	1324	GTG	191;189;190	G;T;G	180;177;180	penA.19.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3922	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2429	160.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1826	1828	ACC	212;213;214	A;C;C	200;199;201	penA.19.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3922	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2429	160.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1880	1882	GCG	187;189;191	G;C;G	166;153;161	penA.19.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3922	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2429	160.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1880	1882	GCG	187;189;191	G;C;G	166;153;161	penA.19.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3922	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2429	160.9	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2003	2005	GGT	171;169;166	G;G;T	160;158;153	penA.19.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3922	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2429	160.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2012	2014	GGC	160;157;159	G;G;C	149;146;146	penA.19.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3922	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2429	160.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2030	2032	CCG	133;136;133	C,G;C;G	96,1;100;99	penA.19.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5694	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3087	183.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1678	1680	CCG	210;212;216	C;C;G	197;201;201	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2296	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1717	132.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	572	572	C	139	C,T	124,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1000	1002	AAT	19;18;18	A;A;T	19;18;18	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1003	1005	AAT	18;18;18	A;A;T	18;18;18	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1027	1029	GCA	24;24;24	G;C;A	24;24;24	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1050	1052	GTA	23;22;21	G;T;A	23;22;21	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1056	1058	AAC	21;20;19	A;A;C	21;20;19	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1060	1064	TGGCG	19;18;18;24;25	T;G;G;C;G	19;18;18;24;24	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1066	1068	GCT	28;30;32	G;C;T	28;30;31	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	A251V	NONSYN	751	753	GCG	1105	1107	GTG	44;44;44	G;T;G	42;39;41	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1126	1128	TTA	52;54;54	T;T;A	50;53;53	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1171	1173	CAT	59;54;49	C;A;T	57;52;48	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1174	1176	AGT	50;50;50	A;G;T	49;49;48	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	344	porB1a	984	297	90.37	porB1a.l15.c17.ctg.1	1276	24.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1183	1185	TAC	51;51;51	T;A;C	49;49;50	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2980	porB1b	1035	1035	98.94	porB1b.l15.c30.ctg.1	1536	192.3	0	.	p	.	0	R143G	NONSYN	427	429	AGA	791	793	GGA	280;275;270	G;G;A	264;263;257	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2980	porB1b	1035	1035	98.94	porB1b.l15.c30.ctg.1	1536	192.3	0	.	p	.	0	.	INDELS	629	630	AA	994	996	TAG	251;252;254	T;A;G	239;242;243	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2980	porB1b	1035	1035	98.94	porB1b.l15.c30.ctg.1	1536	192.3	0	.	p	.	0	.	MULTIPLE	631	633	TAC	998	1001	CAAT	262;259;257;256	C;A;A;T	252;248;249;246	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2980	porB1b	1035	1035	98.94	porB1b.l15.c30.ctg.1	1536	192.3	0	.	p	.	0	N212fs	FSHIFT	634	634	A	1003	1003	T	254	T	243	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2980	porB1b	1035	1035	98.94	porB1b.l15.c30.ctg.1	1536	192.3	1	SNP	p	G120K	0	.	.	358	360	GGT	722	724	GGT	238;238;240	G;G;T	227;227;223	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2980	porB1b	1035	1035	98.94	porB1b.l15.c30.ctg.1	1536	192.3	1	SNP	p	A121D	0	.	.	361	363	GCC	725	727	GCC	240;241;243	G,T;C,T;C	224,1;228,1;232	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2980	porB1b	1035	1035	98.94	porB1b.l15.c30.ctg.1	1536	192.3	1	SNP	p	A121N	0	.	.	361	363	GCC	725	727	GCC	240;241;243	G,T;C,T;C	224,1;228,1;232	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11054	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4917	224.1	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2005	2007	CAT	275;271;271	C;A;T	256;251;251	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1264	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1067	117.7	1	SNP	p	V57M	1	.	.	169	171	ATG	506	508	ATG	250;251;248	A;T;G	244;244;240	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
